Abstract
Molecular targeted therapies have changed the landscape of cancer research. Agonistic monoclonal antibodies (MoAbs) targeting TRAIL-death receptors (TRAIL-Rs) have been developed and currently used in clinical trials. Binding of such antibodies to TRAIL-R1 and TRAIL-R2 results in death inducing signalling complex (DISC) formation and induction of apoptosis, which represents a natural mechanism of cell growth control and an ideal target for drug development. These novel fully humanized compounds have been associated with conventional chemotherapy in the treatment of advanced solid malignancies, including different types of lymphoma. Here we outline the rationale and potential of a new molecular-based strategy combining agonistic anti-TRAIL-death receptor monoclonal antibodies plus the pioneer of the new biological frontiers of cancer therapy: rituximab.
Keywords: TRAIL, TRAIL receptors, anti-TRAIL-R agonistic antibodies, haematological malignancies, rituximab
Current Pharmaceutical Design
Title: A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Volume: 14 Issue: 21
Author(s): Silvia Sancilio, Vittorio Grill and Roberta Di Pietro
Affiliation:
Keywords: TRAIL, TRAIL receptors, anti-TRAIL-R agonistic antibodies, haematological malignancies, rituximab
Abstract: Molecular targeted therapies have changed the landscape of cancer research. Agonistic monoclonal antibodies (MoAbs) targeting TRAIL-death receptors (TRAIL-Rs) have been developed and currently used in clinical trials. Binding of such antibodies to TRAIL-R1 and TRAIL-R2 results in death inducing signalling complex (DISC) formation and induction of apoptosis, which represents a natural mechanism of cell growth control and an ideal target for drug development. These novel fully humanized compounds have been associated with conventional chemotherapy in the treatment of advanced solid malignancies, including different types of lymphoma. Here we outline the rationale and potential of a new molecular-based strategy combining agonistic anti-TRAIL-death receptor monoclonal antibodies plus the pioneer of the new biological frontiers of cancer therapy: rituximab.
Export Options
About this article
Cite this article as:
Sancilio Silvia, Grill Vittorio and Di Pietro Roberta, A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies, Current Pharmaceutical Design 2008; 14 (21) . https://dx.doi.org/10.2174/138161208785294582
DOI https://dx.doi.org/10.2174/138161208785294582 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Natural Products Based Anticancer Agents
Mini-Reviews in Organic Chemistry Quinones Derived from Plant Secondary Metabolites as Anti-cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) Searching Drug-Like Anti-cancer Compound(s) Based on G-Quadruplex Ligands
Current Pharmaceutical Design Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Transition Metal-Based Prodrugs for Anticancer Drug Delivery
Current Medicinal Chemistry Repressing the Activity of Protein Kinase CK2 Releases Mitochondria-Mediated Apoptosis in Cancer Cells
Current Drug Targets Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry The Proteasome as a Therapeutic Target for Lung Fibrosis
Current Enzyme Inhibition Angiogenesis in Lymphoma: A Short Review
Current Molecular Medicine Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Hemopoiesis in Ph-Negative Chronic Myeloproliferative Disorders
Current Stem Cell Research & Therapy TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Somatostatin and Octreotide on the Treatment of Acute Pancreatitis - Basic and Clinical Studies for Three Decades
Current Pharmaceutical Design